Overexpression of Full-Length ETV1 Transcripts in Clinical Prostate Cancer Due to Gene Translocation
2011

ETV1 Overexpression in Prostate Cancer

Sample size: 66 publication Evidence: moderate

Author Information

Author(s): Gasi Delila, van der Korput Hetty A., Douben Hannie C., de Klein Annelies, de Ridder Corrina M., van Weerden Wytske M., Trapman Jan

Primary Institution: Erasmus University Medical Centre, Rotterdam, The Netherlands

Hypothesis

The study investigates the genetic background of full-length ETV1 overexpression and its biological properties in prostate cancer.

Conclusion

Full-length ETV1 overexpression in clinical prostate cancer is due to genomic rearrangements involving different chromosomes.

Supporting Evidence

  • ETV1 is overexpressed in a subset of clinical prostate cancers as a fusion transcript with many different partners.
  • Break-apart FISH showed genomic rearrangement of the ETV1 gene in five out of six patient samples with overexpression.
  • The study identified a novel, N-truncated ETV1 isoform with the same activity as full-length ETV1.

Takeaway

Some prostate cancer patients have too much of a protein called ETV1 because their genes are mixed up, which can help the cancer grow.

Methodology

The study used quantitative reverse transcriptase reaction (QPCR) and break-apart FISH to analyze ETV1 expression and genomic rearrangements in prostate cancer samples.

Limitations

The study focused on a limited number of samples and did not explore all potential genomic rearrangements.

Participant Demographics

The study involved clinical prostate cancer samples from a cohort of 66 patients.

Digital Object Identifier (DOI)

10.1371/journal.pone.0016332

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication